{"id":"NCT01619878","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg","officialTitle":"An Open-label, Single-arm Study to Evaluate the Efficacy, Safety and PK of Artemether-lumefantrine Dispersible Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants <5 kg Body Weight","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-10","primaryCompletion":"2014-07","completion":"2014-07","firstPosted":"2012-06-14","resultsPosted":"2015-06-17","lastUpdate":"2015-06-17"},"enrollment":20,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Uncomplicated Falciparum Malaria"],"interventions":[{"type":"DRUG","name":"Artemether-lumefantrine (COA566)","otherNames":["Artemether-lumefantrine, COA566"]}],"arms":[{"label":"Cohort 1","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to obtain efficacy, safety and pharmacokinetic (PK) data following treatment with artemether-lumefantrine dispersible tablet in infants \\< 5 kg of body weight (BW) with uncomplicated falciparum malaria.","primaryOutcome":{"measure":"Polymerase Chain Reaction (PCR) Corrected 28 Day Parasitological Cure Rate","timeFrame":"28 days","effectByArm":[{"arm":"Cohort 1","deltaMin":16,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":7,"countries":["Benin","Burkina Faso","Nigeria","Republic of the Congo","Togo"]},"refs":{"pmids":["25886021"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":20},"commonTop":["Malaria","Anaemia","Bronchitis","Pyrexia","Vomiting"]}}